Kinase Inhibitors: Innovative Delivery Strategies and Anticancer Potential
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".
Deadline for manuscript submissions: 31 January 2025 | Viewed by 142
Special Issue Editors
Interests: oral drug delivery; ADME/DMPK; anticancer agents; pyrazolo[3,4-d]pyrimidines; analytical; kinase inhibitors
Interests: anticancer agents; targeted delivery; analytics; medicinal chemistry; ADME/DMPK
Special Issues, Collections and Topics in MDPI journals
Interests: anticancer nanoformulations; oral drug delivery; drug discovery; gut microbiota; ADME/DMPK; analytical chemistry; validation of chromatographic methods
Special Issue Information
Dear Colleagues,
Cancer remains a major global health issue, with huge efforts being made to develop more effective and targeted treatments. The dynamic landscape of cancer research has undergone a remarkable transformation with the advent of targeted therapies, most notably the development of kinase inhibitors. In this context, the discovery and development of anticancer drugs, such as kinase inhibitors, has been marked as a turning point in the treatment of different types of tumors. Indeed, these enzymes, responsible for catalysing phosphorylation reactions, are central to various cellular processes such as cell division, cell death, transcription and metabolism. Their dysregulation has been implicated in a wide range of diseases, including many forms of cancer. The success of imatinib, the first oral tyrosine kinase inhibitor approved by the Federal Drug Administration (FDA) in 2001 for chronic myelogenous leukemia, has paved the way for the extensive use of kinase inhibitors (KIs) as anticancer agents.
Recent advances in drug delivery systems have significantly enhanced the efficacy and specificity of kinase inhibitors. Innovative delivery platforms, such as nanoparticles, liposomes, dendrimers and polymeric micelles, are being utilized to improve the targeted delivery of kinase inhibitors to tumor sites. These technologies aim to increase drug accumulation in cancerous tissues, reduce systemic toxicity and overcome mechanisms of drug resistance. Additionally, stimuli-responsive delivery systems that release drugs in response to specific tumor microenvironment conditions, such as pH, temperature or enzymatic activity, are being explored to further refine the precision of these treatments.
This Special Issue of Pharmaceutics welcomes original research papers and high-impact reviews focused on the development of new kinase inhibitors, as well as drug delivery and formulation studies, biological and ADME/DMPK evaluation. We encourage contributions that highlight novel drug delivery strategies and their role in enhancing the therapeutic potential of kinase inhibitors in cancer treatment.
Dr. Federica Poggialini
Dr. Elena Dreassi
Dr. Chiara Vagaggini
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- kinase inhibitors
- ADME
- DMPK
- formulation studies
- anticancer activity
- drug discovery
- targeted therapy
- drug delivery
- innovative delivery platforms
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
